Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 4:37 PM
Ignite Modification Date: 2025-12-25 @ 2:27 PM
NCT ID: NCT06312566
Description: A TEAE was defined as any AE with a start date/time on or after the first dose of IMP or any unresolved event already present before administration of IMP that worsened in intensity following exposure to IMP. SS included all randomized participants who received at least 1 dose of the IMP.
Frequency Threshold: 5
Time Frame: From Baseline to end of Safety Follow-Up (up to 25 days)
Study: NCT06312566
Study Brief: A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
BRV Tablet Participants received BRV 50 mg tablet twice daily on Day 1 and Day 2 followed by a single administration on Day 3, under fasting conditions in Dosing Period 1 and Dosing Period 2 of the study. 0 None 0 63 2 63 View
BRV Dry Syrup Participants received BRV 50 mg dry syrup twice daily on Day 1 and Day 2 followed by a single administration on Day 3, under fasting conditions in Dosing Period 1 and Dosing Period 2 of the study. 0 None 0 64 6 64 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Dizziness NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA ver 18.1 View
Somnolence NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA ver 18.1 View